Schnidar et al. (59) reported that the HH/GLI pathway cooperates with the epidermal growth factor receptor (EGFR) pathway to synergistically induce oncogenic transformation; and that pharmacologic inhibition of both EGFR and HH-Gli effectively reduces the growth of basal cell carcinoma (BCC) cell lines derived from mice with activated HH/GLI signaling. This evidence concerns the gene EGFR and basal cell carcinoma.